Devon Energy Corp vs Merck & Co., Inc. — how do they compare? Devon Energy Corp trades at $48.95 (market cap $53.81B), while Merck & Co., Inc. trades at $144.98 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 6.5× Devon Energy Corp's market cap, and Devon Energy Corp pays the higher dividend (2.62%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Merck & Co., Inc. for 98 Days on average.
| DVN | MRK | |
|---|---|---|
Market Cap | $53.81B | $351.28B |
Volume | 11,556,740 | 7,969,665 |
Sector | Energy | Health |
52-Week High | $52.07 | $156.43 |
52-Week Low | $31.74 | $82.49 |
Typical Hold Time | 136 Days | 98 Days |
Enterprise Value | $64.55B | $398.04B |
Dividend Yield | 2.62% | 2.39% |
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $47.88, down 0.29% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $62.40 implying significant upside. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss, while fundamentals show solid profitability with a 16.67% net income margin and attractive valuation multiples. Activist investor pressure for strategic alternatives, including a potential sale, has been a key recent development.
The outlook is positive, supported by strong analyst buy ratings (71.87%) and projected revenue growth to $19.7B in 2026. Key risks include oil price volatility, execution of asset sales, and rising debt levels, but the current valuation and cash flow generation present a compelling opportunity for value-oriented investors.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →